Sotera Health Company (SHC) Stock Price & How to Invest

Last updated November 2026

Short answer

Sotera Health (Nasdaq: SHC) is the outsourced sterilization and lab-testing contractor that sits between medical device makers and the operating room, running 62 facilities in more than 50 countries for over 40 of the top 50 device companies. A screener sees one healthcare-services business at roughly $1.23 billion of revenue on a ~26x trailing P/E at ~$15.83 as of November 20, 2026. The structure underneath is three units with very different economics: Sterigenics (contract sterilization) at ~$755.8 million of 2025 revenue and a 54.6% segment margin, Nordion (cobalt-60 supply) at ~$187.6 million and 57.3%, and Nelson Labs (testing and advisory) at ~$220.2 million and 33.3%. The trailing P/E also misleads, because reported earnings have absorbed years of ethylene oxide litigation charges, including a $408.0 million Illinois settlement finalized in June 2023. The shares are down ~10.5% year to date after falling ~12.5% over the past month, even though third-quarter results on November 3 beat estimates.

SHC stock price

As of 2026-11-20, Sotera Health Company (SHC) last closed at $15.91, down 2.6% over the past year. Over the past 52 weeks it has traded between $13.13 and $19.57.

SHC last close
$15.91
1 day
-1.85%
1 month
-10.47%
1 year
-2.57%
52-week range
$13.13 to $19.57
Last close
2026-11-20

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Sotera Health Company's investor relations page. Walnut is informational, not investment advice.

SHC key stats

At $15.91 on November 20, 2026, Sotera Health Company (SHC) has a market cap of $4.5B and a P/E of 26.5 on trailing earnings (14.9 on forward earnings).

Market cap
$4.5B
P/E (trailing)
26.5
P/E (forward)
14.9
EPS (trailing 12 months)
$0.60
Price to book
6.2
Beta
1.93

Market cap, P/E and yield are measured at the $15.91 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Sotera Health Company (SHC)?

The last two weeks for Sotera Health Company, as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • SHC closed at $15.91 on November 20, 2026, down 4.2% over the past five trading days (from $16.61).

Sotera Health Company filed no current, quarterly or annual report with the SEC in the last two weeks.

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

Sotera Health Company (SHC) latest quarter

Sotera Health reported revenue of $325 million for Q3 2026, up 4% from a year earlier (Sotera Health, Nov 3, 2026).

Revenue
$325 million
up 4% from a year earlier
Diluted EPS (GAAP)
$0.20
up 18% from a year earlier
Sterigenics
$209 million
up 9% from a year earlier

Source: Sotera Health Q3 2026 results, Nov 3, 2026. Full earnings breakdown

What does Sotera Health Company (SHC) do?

Sotera Health provides the step a medical product has to pass before it can be sold: killing whatever is living on it. Sterigenics, the largest of the three units, runs contract sterilization plants using gamma irradiation, ethylene oxide and electron beam, and has done that work for more than 90 years. Nordion supplies the cobalt-60 that makes gamma sterilization possible, along with the irradiator systems that house it, and the company estimates gamma handles roughly 30% of single-use medical device sterilization worldwide. Nelson Labs sells microbiological and analytical chemistry testing (over 900 distinct tests) plus the regulatory advisory work customers need to validate a sterilization method and defend it to a regulator. Revenue for the twelve months to September 30, 2026 was ~$1.23 billion across 62 facilities and more than 3,000 employees. The customer list is concentrated at the top of the industry: over 40 of the top 50 medical device companies and nine of the ten largest global pharmaceutical companies. More than 90% of both Sterigenics and Nordion revenue in 2025 came from customers on multi-year contracts, so volumes track device production rather than any discretionary spending cycle.

Pricing and volume are the two levers the numbers turn on, and both worked through most of 2026. Second-quarter revenue rose 9.2% to $321.4 million, with Sterigenics up 8.6%, Nordion up 15.8% on the timing of cobalt-60 harvests, and Nelson Labs up 6.3% after a weak 2025. Third-quarter revenue was ~$324.9 million, up 4.4% in constant currency: Sterigenics grew 8.2% and Nelson Labs 9.2% in constant currency, while Nordion fell 12.4% on harvest timing. Adjusted EBITDA rose 4%, and adjusted EPS of $0.29, up 12%, beat the ~$0.27 consensus. Management reaffirmed full-year revenue and adjusted EBITDA guidance on a constant-currency basis (the August ranges were $1.236 billion to $1.254 billion of revenue and $634 million to $643 million of adjusted EBITDA), raised its Nelson Labs growth outlook to low-to-mid single digits, and said Sterigenics would not see its usual sequential fourth-quarter growth. It also described softness among European medical device customers that began in the middle of the third quarter and continued into the fourth, with the US relatively stable, and expects a currency headwind of more than 100 basis points in the fourth quarter. The capital structure explains much of the equity story. Sotera carried ~$2.28 billion of total debt against ~$413 million of cash at September 30, 2026, and net leverage fell to 2.9x, inside the company's 2.0x to 3.0x target range; Moody's upgraded its credit rating. A May 2026 term loan repricing cut the spread by 25 basis points and saves ~$3.5 million a year. At ~$15.83 a share on November 20, 2026 the equity is worth ~$4.52 billion, and adding ~$1.87 billion of net debt gives an enterprise value near $6.4 billion, roughly 11x trailing EBITDA. The shares jumped ~12.9% on the day of the third-quarter report but have since fallen, ending ~12.5% lower over one month, ~18.9% lower over three months and ~10.5% lower year to date, roughly flat over twelve months. JPMorgan had downgraded the stock to underweight from neutral on October 14, 2026 with a $17 price target, while RBC said in November that Sotera has a favorable setup heading into 2027. Management plans to give 2027 expectations in February 2027 and expects a meaningful capital-spending step-down, supporting a $500 million to $600 million free cash flow objective. The gap between that multiple and what infrastructure-like healthcare assets usually fetch is where the ethylene oxide tort docket sits.

What's driving Sotera Health Company (SHC)?

1. Contracted volume and repeat pricing

More than 90% of Sterigenics revenue and roughly 90% of Nordion revenue in 2025 came from customers under multi-year contracts, many carrying variable price clauses. Sterigenics grew 8.3% in 2025 to $755.8 million on 4.1% pricing and 3.6% volume/mix, then added 9.1% in the first half of 2026 to $397.7 million and 8.2% in constant currency in the third quarter, with pricing at the high end of its 3-4% long-term range. Segment income margin was 54.6% for 2025 and improved another 53 basis points in the second quarter of 2026 and 57 basis points in the third. Sterilization is a required step, not a purchase decision, so the volume base moves with device production instead of with hospital capital budgets. The caveat for the fourth quarter is Europe: management saw softer demand among European device customers from mid-third quarter and does not expect Sterigenics' usual sequential fourth-quarter growth.

2. Nordion's cobalt-60 position and the harvest cycle

Nordion is the leading global supplier of cobalt-60 outside state-linked producers, and its revenue is lumpy because cobalt is harvested from nuclear reactors on a schedule, not manufactured continuously. Second-quarter 2026 revenue rose 15.8% to $49.1 million and first-half revenue rose 21.6% to $91.2 million, driven mostly by harvest timing; the same timing then cut third-quarter revenue 12.4% and segment income 11.4%, although segment margin rose 71 basis points. Segment margin was 57.3% in 2025, the highest of the three units. Cobalt-60 decays at roughly 12% a year, so customers replenish sources whether or not their own volumes grow, giving the unit a subscription-like floor. Competing production sits in Argentina, India, Russia and China, and the Russian supplier has faced export constraints in recent years.

3. Leverage coming down, and interest expense with it

Net leverage fell to 3.0x at June 30, 2026 and 2.9x at September 30, inside the 2.0x to 3.0x range management has pointed at since the IPO, and Moody's upgraded the company's rating. Interest expense, net was $69.2 million in the first half of 2026 against $81.5 million a year earlier, a $12.4 million reduction that drops straight through. In May 2026 the company repriced ~$1.42 billion of first lien term loans, cutting the spread to SOFR plus 2.25% and saving ~$3.5 million of annual interest, and full-year 2026 interest expense guidance was lowered to $135 million to $142 million in August. Operating cash flow was $111 million in the third quarter and $228 million year to date. With ethylene oxide facility upgrades due to finish in the first quarter of 2027, management expects capital spending to step down meaningfully, toward a $500 million to $600 million free cash flow objective, and lists organic growth, sterilization acquisitions, buybacks and debt paydown as uses under evaluation.

4. The sponsor register cleared out

Warburg Pincus and GTCR took Sotera public in November 2020 and held control for more than five years through a stockholders agreement carrying board designation rights. Affiliates sold 25,000,000 shares at $15.27 on March 6, 2026 and a final 31,838,253 shares at $15.168 on May 13, 2026, after which no sponsor ownership remains and the stockholders agreement terminated by its terms. Sponsor-designated directors have since left the board: Constantine Mihas of GTCR effective March 16, 2026 and James Neary of Warburg Pincus effective August 13, 2026. Alton Shader took over as chief executive from Michael Petras under an offer dated May 1, 2026. The float is now the whole company, and the queue of scheduled secondary sales that capped the stock is gone.

What are the risks to Sotera Health Company (SHC)?

The ethylene oxide tort docket is the dominant, partly quantified risk. Sterigenics and affiliates have already agreed to pay $408.0 million to settle over 880 Willowbrook, Illinois claims (term sheets January 2023, finalized June 2023), $35 million for 79 Atlanta claims in October 2023, $30.9 million for 97 more Illinois claims in April 2025 and $34.0 million for 129 further Illinois claims in July 2025. A single Cook County jury returned a $358.7 million verdict in 2022, of which $320 million was punitive. As of July 31, 2026 the open inventory was approximately 500 Georgia personal-injury and wrongful-death claims, ~305 Georgia property-devaluation suits, ~150 California claims tied to the Vernon facilities with initial trials scheduled for January and April 2027, and ~15 Illinois cases. The company states that losses in the remaining cases are not probable and carries no reserve for them, so an adverse verdict would land unprovided for. Georgia rulings currently favor the defense, since the trial court excluded plaintiffs' general causation experts and entered summary judgment in March 2026, but those rulings are on appeal, with an appellate decision expected in spring 2027. All Illinois cases have been assigned to one judge and pretrial proceedings are under way. Regulation is the second exposure. The EPA's March 2024 NESHAP rules require permanent total enclosure capture, higher control efficiencies and continuous emissions monitoring at ethylene oxide sterilizers. A July 2025 Clean Air Act proclamation granted Sotera's facilities a two-year exemption, and a January 2026 suit in the District of Columbia seeks to invalidate that exemption and restore the original deadline. Capital expenditure guidance of $200 million to $225 million for 2026, against ~$1.24 billion of consensus revenue, reflects part of that compliance burden and keeps free cash flow far below adjusted EBITDA. A separate FIFRA interim decision issued in January 2025 phases in tighter worker exposure limits over one to ten years. Three smaller items sit behind those. Total debt of ~$2.28 billion against book equity of roughly $0.7 billion (price to book is ~6.2x) leaves limited cushion if volumes stall. The United States has a single industry supplier of ethylene oxide. And Nelson Labs shrank 3.9% in 2025 and grew only 0.9% in constant currency in the first half of 2026 before recovering to 9.2% in the third quarter, when its segment margin fell 199 basis points to 32.1% on business mix, a reminder that the testing unit does not behave like the sterilization ones. Demand and sentiment are the last item. Management said European medical device customers turned less optimistic from the middle of the third quarter into the fourth, and two analysts cut fourth-quarter estimates over the 60 days to mid-November, taking consensus to ~$0.26 of EPS on ~$318 million of revenue, roughly flat year over year. After a run to the $19.85 52-week high, the stock met a JPMorgan downgrade to underweight with a $17 target in October and has since fallen below that level, closing at ~$15.83 on November 20, 2026.

What is the Sotera Health Company (SHC) forecast?

9 analysts publish price targets on SHC, averaging $21.44 as of November 2026, or +34.8% against the $15.91 share price on November 20, 2026. The published targets run from $15.00 to $25.00, a moderate spread, and the ratings split 8 buy, 1 hold, 1 sell. Over the last six months there have been 5 raises and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full SHC forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is SHC a buy or a sell?

We give no verdict on Sotera Health Company. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Contracted volume and repeat pricing. More than 90% of Sterigenics revenue and roughly 90% of Nordion revenue in 2025 came from customers under multi-year contracts, many carrying variable price clauses. The most optimistic published target, $25.00, assumes this works close to its best case.

The case against. The ethylene oxide tort docket is the dominant, partly quantified risk. The most pessimistic target, $15.00, is roughly what SHC is worth if this bites instead.

Read the full bull and bear case on SHC, including what would have to change to break either one. Walnut is not an investment adviser.

Has Sotera Health Company (SHC) split its stock?

No. Sotera Health Company (SHC) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is Sotera Health Company (SHC) valued?

Market cap, P/E and dividend yield at today's price are in the SHC key stats above. The business figures below come from Sotera Health Company's reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~$1.23 billion for the twelve months to September 30, 2026, against ~$1.16 billion in fiscal 2025 and ~$1.10 billion in fiscal 2024. Third-quarter 2026 revenue was ~$324.9 million, up 4.4% in constant currency, after 9.2% growth in the second quarter. Full-year revenue guidance ($1.236 billion to $1.254 billion as of August) was reaffirmed on a constant-currency basis on November 3, 2026; consensus is ~$1.24 billion for 2026 and ~$1.31 billion for 2027.
  • Earnings and EPS: GAAP net income of ~$173.5 million for the twelve months to September 30, 2026, a ~14.1% net margin, against $77.9 million in fiscal 2025 and $44.4 million in fiscal 2024; trailing diluted EPS is ~$0.60. Q3 2026 net income was ~$58.4 million and adjusted EPS of $0.29, up 12%, beat the ~$0.27 consensus, the fifth straight quarter at or above estimates. Consensus adjusted EPS is ~$0.98 for 2026 and ~$1.07 for 2027.
  • Segment mix and margins: For fiscal 2025, Sterigenics contributed $755.8 million of revenue (65% of the total) at a 54.6% segment margin, Nordion $187.6 million (16%) at 57.3%, and Nelson Labs $220.2 million (19%) at 33.3%. In Q3 2026 Sterigenics grew 8.2% and Nelson Labs 9.2% in constant currency while Nordion fell 12.4% on cobalt harvest timing; Nelson Labs' segment margin was 32.1%. Management expects full-year adjusted EBITDA margin roughly flat, near 51%.
  • Cash flow and capital spending: Operating cash flow was $111 million in Q3 2026 and $228 million year to date. Capital expenditure guidance for 2026 is $200 million to $225 million, close to 17% of revenue, so Yahoo's trailing free cash flow of ~$146 million is a small fraction of EBITDA. Management expects a meaningful capex step-down after ethylene oxide facility upgrades finish in Q1 2027, toward a $500 million to $600 million free cash flow objective.
  • Balance sheet: Total debt of ~$2.28 billion and cash of ~$413 million at September 30, 2026, for net debt near $1.87 billion and net leverage of 2.9x, inside the 2.0x to 3.0x target; Moody's upgraded the rating. The May 2026 repricing set ~$1.42 billion of term loans at SOFR plus 2.25%, and the $600 million revolver was undrawn at June 30.
  • Market pricing: The shares closed at ~$15.83 on November 20, 2026, against a 52-week range of $13.09 to $19.85, for a market capitalization of ~$4.52 billion. Enterprise value is roughly $6.4 billion, or ~11.1x trailing EBITDA on Yahoo Finance's ~$584 million basis. Trailing P/E is ~26x, forward ~15x on consensus 2027 EPS of ~$1.07, and price to trailing sales ~3.7x. Sotera pays no dividend.
  • Next report: Fourth-quarter 2026 results and 2027 expectations are due in February 2027; consensus for the December quarter is ~$0.26 of adjusted EPS on ~$317.5 million of revenue.

As of November 2026: Roughly 11x enterprise value to EBITDA is a modest price for a business earning around 51% adjusted EBITDA margins on largely contracted revenue from a regulated, hard-to-replicate asset base. The discount is the litigation: Sotera carries no reserve for the ~970 ethylene oxide claims outstanding as of July 31, 2026, so the multiple embeds an unpriced tail, not a known cost. The ~26x trailing GAAP P/E reflects amortization, interest and settlement charges the adjusted figures strip out, and after a ~19% three-month fall and a softer European outlook the forward multiple has come down to ~15x.

Who competes with Sotera Health Company (SHC)?

Outsourced contract sterilization

Sterigenics' one direct global competitor of comparable scale is Applied Sterilization Technologies, the sterilization arm of STERIS plc, which offers the same gamma, ethylene oxide and electron-beam modalities to the same medical device customers. Below that tier sit regional operators such as Cosmed Group and E-BEAM Services, none with a comparable multi-country network. The larger structural competitor is insourcing: Medtronic, Becton Dickinson, Johnson & Johnson MedTech and other large manufacturers have invested in in-house sterilization capacity, which removes outsourced volume permanently once built. Competition turns on proximity to a customer's plant, validated capability in each modality and regulatory track record more than on headline price.

Cobalt-60 and radiation sources

Nordion's competition is unusual because most rival cobalt-60 production is state-linked. Producers in Argentina, India, Russia and China supply mainly domestic and nearby markets, and the Russian supplier has faced export difficulty given the geopolitical situation. Expansion by any of them would require large capital investment in reactor capacity. The more consequential threat is technological substitution: X-ray sterilization generates radiation from electricity and needs no cobalt source at all, and electron beam serves a growing share of low-density products. For the high specific activity medical cobalt-60 used in Gamma Knife radiosurgery, Sotera names suppliers in China, Sweden and North America as competitors.

Lab testing and regulatory advisory

Nelson Labs competes in a fragmented outsourced testing market against Eurofins Scientific, SGS, Charles River Laboratories, NAMSA, Intertek and Bureau Veritas, as well as device makers' own internal labs. Buyers weight turnaround time and regulatory credibility heavily, since a delayed biocompatibility or package-integrity result can hold up a submission. The unit is the most economically sensitive of Sotera's three, running a 33.3% segment margin in 2025 against 54.6% and 57.3% at the other two, and it shrank 3.9% that year while both sterilization units grew above 8%.

What stocks are similar to Sotera Health Company (SHC)?

Other names that sit close to SHC: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Sotera Health Company (SHC)

There are three common ways to get SHC exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so SHC sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where SHC fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Sotera Health Company (SHC)

As of November 2026, Sotera Health is a high-margin, contract-heavy sterilization franchise (adjusted EBITDA margins around 51% on trailing revenue of ~$1.23 billion) that has cleared its private equity overhang and brought net leverage down to 2.9x, while roughly 970 ethylene oxide claims remain open in Georgia, California and Illinois. At ~$15.83 on November 20, 2026, down from ~$17.94 in mid-October, about 11x enterprise value to trailing EBITDA and ~15x forward earnings, the market is paying for mid-single-digit organic growth against an unreserved legal tail and a softer European device market that management flagged on its third-quarter call.

More on Sotera Health Company (SHC)

Whether SHC is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is SHC a buy or a sell?, and where the stock could go from here in the SHC stock forecast.

For income investors, whether SHC pays a dividend and how the payout looks is covered in does SHC pay a dividend? And to weigh SHC against a peer, read the full side-by-side comparisons: SHC vs STE and SHC vs BEAM.

Wondering how SHC fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Sotera Health Company

Ask Walnut's AI anything about SHC and see how it fits what you own.

FAQ

What does Sotera Health do?

+

Sotera Health is a contract sterilization and testing provider for the medical device, pharmaceutical and food industries, operating 62 facilities in more than 50 countries with over 3,000 employees. It works through three brands. Sterigenics runs outsourced sterilization plants using gamma irradiation, ethylene oxide and electron beam. Nordion supplies cobalt-60, the radioactive source that makes gamma sterilization possible, plus the irradiator systems that hold it. Nelson Labs performs more than 900 microbiological and analytical chemistry tests and sells regulatory advisory services. Most medical products cannot be sold until they have been sterilized and validated, so the work is a required step in a customer's supply chain rather than an optional one. Over 40 of the top 50 device makers and nine of the ten largest pharmaceutical companies are customers.

Why does Sotera Health stock trade at a low multiple for its margins?

+

At ~$15.83 on November 20, 2026 Sotera trades near 11x enterprise value to trailing EBITDA, low for a business earning around a 51% adjusted EBITDA margin on largely contracted revenue. Two things account for the gap. The ethylene oxide tort docket is open, with roughly 970 personal-injury and property claims outstanding as of July 31, 2026 and no reserve taken against them, so the potential cost is unquantified, not absent; first California trials are set for January and April 2027. Second, the balance sheet still carries ~$2.28 billion of debt at 2.9x net leverage, which limits how much EBITDA reaches shareholders after $135 million to $142 million of guided 2026 interest and $200 million to $225 million of capital expenditure. In the autumn of 2026 management also flagged softer demand from European device customers.

What is the ethylene oxide litigation against Sotera Health?

+

Sterigenics and related subsidiaries have been sued by individuals alleging cancers and other injuries from low-level environmental exposure to ethylene oxide emitted from sterilization plants. The claims are individual suits, not class actions. A Cook County jury awarded $358.7 million against the company in 2022 over the former Willowbrook, Illinois facility, including $320 million in punitive damages, after which the company agreed in January 2023 to pay $408.0 million to settle over 880 Illinois claims. Further settlements followed: $35 million for 79 Atlanta claims, $30.9 million for 97 Illinois claims in April 2025 and $34.0 million for 129 more in July 2025. As of July 31, 2026 about 500 Georgia personal-injury claims, 305 Georgia property claims, 150 California claims and 15 Illinois cases remain pending. The Georgia appeal is expected to be decided in spring 2027, and the first California trials are scheduled for January and April 2027.

Is there an active securities class action against Sotera Health?

+

No. A securities fraud class action, Oakland County Employees' Retirement System v. Sotera Health Company, case number 1:23-cv-00143 in the U.S. District Court for the Northern District of Ohio, was filed in January 2023 over the company's ethylene oxide disclosures and named executives, directors, the private equity sponsors and IPO underwriters. The district court dismissed it in March 2025, and a federal appeals panel affirmed the dismissal in February 2026. The Form 10-Q for the quarter ended June 30, 2026, filed on August 6, 2026, discloses ethylene oxide tort litigation and no pending securities case. The distinction matters when reading headlines about Sotera: the personal-injury claims are ongoing and material, while the shareholder fraud claim was resolved in the company's favor.

Does Sotera Health pay a dividend?

+

Sotera Health pays no dividend and has not paid one since its November 2020 initial public offering. Cash generation goes to debt reduction and capacity investment instead. The 2026 plan calls for $200 million to $225 million of capital expenditure against guided revenue of $1.236 billion to $1.254 billion, close to 17% of sales, covering cobalt-60 supply, new sterilization capacity and the emissions control equipment required under EPA rules. Interest expense of $135 million to $142 million absorbs more. Net leverage reached 3.0x at June 30, 2026 and 2.9x at September 30, inside the company's 2.0x to 3.0x target range. On the third-quarter call management said share repurchases and debt paydown are under evaluation alongside organic growth and sterilization acquisitions, ahead of an expected capex step-down in 2027. No dividend has been announced.

Do Warburg Pincus and GTCR still own Sotera Health?

+

Not anymore. Warburg Pincus and GTCR, which controlled Sotera Health from before its 2020 IPO, completed their exit during 2026. Selling stockholders affiliated with the sponsors sold 25,000,000 shares at $15.27 per share on March 6, 2026 and a final 31,838,253 shares at $15.168 per share on May 13, 2026. Sotera issued no shares and received no proceeds in either transaction. The 2020 stockholders agreement, which gave the sponsors board designation rights and other governance powers, terminated on May 13, 2026. Sponsor-designated directors have stepped down since: Constantine Mihas of GTCR effective March 16, 2026 and James Neary of Warburg Pincus effective August 13, 2026, leaving an eleven-member board. The share count is now entirely public float.

Who are Sotera Health's competitors?

+

The direct competitor at global scale is STERIS plc, whose Applied Sterilization Technologies segment offers the same gamma, ethylene oxide and electron-beam services to the same customers. Regional contract sterilizers such as Cosmed Group and E-BEAM Services compete in individual markets. A quieter competitor is insourcing, since large device manufacturers can and do build their own sterilization capacity. Nordion's rivals in cobalt-60 are mainly state-linked producers in Argentina, India, Russia and China that serve domestic markets, alongside X-ray and electron-beam technologies that need no cobalt source. Nelson Labs competes with Eurofins Scientific, SGS, Charles River Laboratories, NAMSA, Intertek and Bureau Veritas. Switching a validated sterilization provider requires product revalidation, and that friction is why the sterilization units hold share more firmly than the testing unit.

How much debt does Sotera Health have?

+

Sotera Health had ~$2.28 billion of total debt and ~$413 million of cash at September 30, 2026, for net debt near $1.87 billion. Net leverage was 2.9x adjusted EBITDA, inside the 2.0x to 3.0x range management has targeted, down from 3.0x at June 30, and Moody's upgraded the company's credit rating after the third quarter. In May 2026 the company repriced about $1.42 billion of first lien term loans, cutting the spread by 25 basis points to SOFR plus 2.25% and saving ~$3.5 million of annual interest, which helped bring 2026 interest expense guidance down to $135 million to $142 million. Available liquidity was ~$950 million at June 30 with the $600 million revolver undrawn.

How did Sotera Health do in its latest quarter?

+

In the third quarter of 2026, reported November 3, Sotera Health posted revenue of ~$324.9 million, up 4.4% in constant currency, and net income of ~$58.4 million. Adjusted EPS of $0.29, up 12%, beat the ~$0.27 consensus, and adjusted EBITDA rose 4%. Sterigenics grew 8.2% and Nelson Labs 9.2% in constant currency, while Nordion fell 12.4% on cobalt-60 harvest timing. Net leverage fell to 2.9x. Management reaffirmed full-year revenue and EBITDA guidance in constant currency, flagged softer European device demand, and plans to give 2027 expectations in February 2027.

How has SHC stock performed in 2026?

+

As of November 20, 2026, SHC closed at ~$15.83, down ~10.5% year to date and roughly flat (~0.3%) over twelve months, after falling ~12.5% over the past month and ~18.9% over three months. The stock reached a 52-week high of $19.85 after a strong second quarter, slipped after JPMorgan downgraded it to underweight with a $17 target on October 14, 2026, jumped ~12.9% on the day of the third-quarter beat and then fell back. The mean analyst target tracked by Yahoo Finance is ~$21.44 across 9 analysts, with a buy rating. Walnut is not an investment adviser, and this summary describes past moves, not future ones.

Why did Sotera Health stock fall after its third-quarter beat?

+

Sotera beat third-quarter estimates on November 3, 2026, and the shares rose ~12.9% that day, but they closed at ~$15.83 on November 20, ~12.5% lower over the month. The company did not tie the move to any single event. On the call management described softer demand among European medical device customers from mid-third quarter into the fourth, said Sterigenics would not show its usual sequential fourth-quarter growth, and expected a currency headwind of more than 100 basis points; consensus for the December quarter fell to ~$0.26 of EPS, about flat year over year.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Sotera Health Company's investor relations page or your broker before making investment decisions.